IP Library Patent Application 13091527
Patent Application
App. No. 13/091,527

COMPOSITIONS AND METHOD FOR ISOLATING MID-LOG PHASE BACTERIA

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/091,527
Abstract

The invention generally relates to compositions and methods for isolating mid-log phase bacteria. In certain embodiments, the invention provides a magnetic particle conjugated to an antibody that includes an epitope specific for mid-log phase bacteria.

Claims (33)

1 . A magnetic particle conjugated to an antibody that comprises an epitope specific for mid-log phase bacteria.

2 . The particle of claim 1 , wherein the antibody is a monoclonal antibody.

3 . The particle of claim 1 , wherein the antibody is a polyclonal antibody.

4 . The particle of claim 1 , further comprising a detectable label.

5 . The particle of claim 4 , wherein the detectable label is an optical label.

6 . The particle of claim 5 , wherein the optical label is a fluorescent label.

7 . The particle of claim 1 , wherein the bacteria is a bacteria found in human blood.

8 . A method for isolating bacteria from a sample, the method comprising:

obtaining a sample comprising bacteria;

introducing a plurality of magnetic particles to the sample, each particle conjugated to an antibody that comprises an epitope specific for mid-log phase bacteria; and

separating particle bound bacteria from the sample.

9 . The method of claim 8 , wherein the sample is a human blood sample.

10 . The method of claim 9 , wherein the bacteria is a bacteria found in human blood.

11 . The method of claim 8 , wherein separating comprises exposing the sample to a magnetic field to separate particle bound bacteria from unbound components of the sample.

12 . The method of claim 8 , wherein the bacteria is viable bacteria.

13 . The method of claim 8 , wherein the antibody is a monoclonal antibody.

14 . The method of claim 8 , wherein the antibody is a polyclonal antibody.

15 . The method of claim 8 , further comprising a detectable label.

16 . The method of claim 15 , wherein the detectable label is an optical label.

17 . The method of claim 16 , wherein the optical label is a fluorescent label.

18 . The method of claim 8 , further comprising diagnosing a disease based upon the bacteria isolated from the sample.

19 . A method for isolating viable bacteria from blood, the method comprising:

obtaining a blood sample comprising viable bacteria;

introducing a plurality of magnetic particles to the sample, each particle conjugated to an antibody that comprises an epitope specific for mid-log phase bacteria; and

separating particle bound bacteria from the sample.

20 . The method of claim 19 , further comprising, eluting the bacteria from the particles.

21 . A method for preparing antibodies for separation of pathogen in a biological sample, the method comprising the steps of:

growing a population of bacteria to mid-log phase;

inactivating said bacteria while preserving antigenicity;

immunizing a mammalian subject with said bacteria;

isolating antigen against said bacteria; and

conjugating said antigen to a magnetic particle.

22 . The method of claim 21 , wherein the bacteria is a bacteria found in human blood.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2016
From: DNA ELECTRONICS, INC.
To: DNAE GROUP HOLDINGS LIMITED
Reel/Frame 041154/0786 →
MERGER Recorded Jan 22, 2016
From: NANOMR, INC.
To: DNA ELECTRONICS, INC.
Reel/Frame 037558/0982 →
CHANGE OF NAME Recorded Dec 29, 2015
From: NANOMR, INC.
To: DNA ELECTRONICS, INC.
Reel/Frame 037372/0788 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2011
From: DRYGA, SERGEY A.; CLARIZIA, LISA-JO ANN
To: NANOMR, INC.
Reel/Frame 026505/0938 →